John Dobak, M.D., President and CEO of DermTech, the leading genomics company in dermatology that is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. Dr. Dobak has served as Founder and CEO of several venture-backed life science companies in San Diego. Dr. Dobak is the President of the JAKK Group, a life sciences technology accelerator, which has created several companies, including Lithera, INNERCOOL Therapies, and CryoGen/CryoCor. These companies have developed and marketed therapeutics, ranging from endovascular hypothermia to treat cardiac arrest to catheter-based treatments for cardiac arrhythmias. They have been financed by top tier investment firms and have achieved exits through acquisition and an IPO. Dr. Dobak and these companies are the recipients of several awards for entrepreneurship and innovation, including UCSD Connect’s Most Innovative New Product and MIT’s TR 100. Dr. Dobak received a bachelor’s degree from UCLA and a medical doctorate from UCSD.
Naysayers have been proven wrong multiple times over as companies across the biotech industry have advanced to deliver diagnostics and detection assays across a number of different cancer types enabling predictive testing, early diagnosis and objective results.